Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643227 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 504
- Enrollment target
NCT00643227 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 504 participants.
The verdict
NCT00643227, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 504 participants
- Enrollment target
Study Summary
The study was performed to confirm that a single, 2.0 g oral dose of azithromycin sustained release (SR) at least as effective as 7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily, when used to treat adults with mild to moderate community acquired pneumonia (CAP), and that both treatments were safe.
Interventions
- DRUG azithromycin SR
- DRUG clarithromycin extended release (ER)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00643227
The ClinicalTrials.gov registry entry for NCT00643227 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which azithromycin SR is the first listed.
NCT00643227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00643227 about?
NCT00643227 is a clinical study titled "A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients". The study was performed to confirm that a single, 2.0 g oral dose of azithromycin sustained release (SR) at least as effective as 7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily, when used to treat adults with mild to moderate community acquired pneumonia (CAP), and that bo...
What is the current status of trial NCT00643227?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 504 participants. The study started on 2003-01. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00643227?
The interventions under investigation include: azithromycin SR (DRUG), clarithromycin extended release (ER) (DRUG).
Who is sponsoring clinical trial NCT00643227?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.